Plasma levels of platelet-enriched microRNAs change during antiplatelet therapy in healthy subjects

Platelets are the main effectors of primary hemostasis but also cause thrombosis in pathological conditions. Antiplatelet drugs are the cornerstone for the prevention of adverse cardiovascular events. Monitoring the extent of platelet inhibition is essential. Currently available platelet function te...

全面介紹

書目詳細資料

發表在:	Frontiers in Pharmacology
Main Authors:	Teresa L. Krammer, Marietta Kollars, Paul A. Kyrle, Matthias Hackl, Sabine Eichinger, Ludwig Traby
格式:	Article
語言:	英语
出版:	Frontiers Media S.A. 2022-12-01
主題:	platelet-enriched microRNA thrombomiR biomarker antiplatelet therapy extracellular vesicle procoagulant vesicle
在線閱讀:	https://www.frontiersin.org/articles/10.3389/fphar.2022.1078722/full